香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 山東新華制藥股份有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於二零二六年 三月二十七日（星期五）上午九時在中華人民共和國（「中國」）山東省淄博市高新區魯泰大 道1號本公司會議室召開董事會會議，會議內容如下： 1、 審議及批准本公司及其附屬公司截至二零二五年十二月三十一日止經審計的年度業績； 2、 審議宣派末期股息事宜（如有）；及 3、任何其他事宜，如適用。 承董事會命 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 公告 董事會會議通知 於本公告日期，本公司董事會由下列董事組成： 執行董事： 賀同慶先生（董事長） 徐文輝先生 侯 寧先生 獨立非執行董事： 潘廣成先生 朱建偉先生 淩沛學先生 張菁菁女士 非執行董事： 徐 列先生 張成勇先生 山東新華制藥股 ...

Core Viewpoint - Xinhua Pharmaceutical has shown a slight increase in stock price and has a significant market presence in the production of analgesic and antipyretic medications, with a focus on flu treatment and other therapeutic areas [1][11]. Group 1: Company Overview - Xinhua Pharmaceutical is a major global producer of analgesic medications, including Ibuprofen and Aspirin, widely used for flu-related symptoms [2][12]. - The company also produces medications for liver disease and has a range of products for treating Helicobacter pylori infections [3][13]. - Xinhua Pharmaceutical has established online sales channels and partnerships with hospitals, clinics, and pharmacies [4][14]. - The company signed a framework cooperation agreement with Alibaba Group in March 2018 to collaborate in various fields, including B2B business and cloud computing [4][14]. - As of September 30, 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion yuan, a year-on-year increase of 0.42%, while net profit decreased by 25.53% to 256 million yuan [9][19]. Group 2: Financial Analysis - The stock's average trading cost is 16.26 yuan, with the current price near a support level of 15.44 yuan [7][18]. - The main capital inflow today was 1.0508 million yuan, accounting for 0.02% of the total, with a ranking of 55 out of 158 in the industry [4][15]. - The distribution of shares is very dispersed, with the main capital accounting for only 7.4% of the total transaction amount [6][17]. - The number of shareholders decreased by 7.60% to 70,700 as of September 30, 2025 [9][20].

Core Viewpoint - The company, XinHua Pharmaceutical, emphasizes its strategy of integrating large-scale research and development, a complete industry chain, and internationalization to enhance its market position in the pharmaceutical sector [1] Group 1: Strategic Focus - The company is building a multi-dimensional layout that includes innovative drugs, specialty raw materials, high-end formulations, and Contract Development and Manufacturing Organization (CDMO) services [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Group 1 - The approved product, Entacapone tablets, is indicated for use alongside standard medications such as Levodopa/Benserazide or Levodopa/Carbidopa [1] - The primary application of Entacapone is to treat Parkinson's disease and address symptoms that are not controlled by existing therapies [1]

新华制药（000756）(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称"新达制药")收 到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。本品配合饮 食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者的血糖控 制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。 ...

智通财经APP讯，新华制药(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称"新达制 药")收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。本品 配合饮食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者的血 糖控制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Group 1 - The approved product, Entacapone, is indicated for use alongside standard medications such as Levodopa/benserazide or Levodopa/carbidopa [1] - Entacapone is specifically aimed at treating Parkinson's disease and addressing motor fluctuations that cannot be controlled by existing therapies [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Saxagliptin and Metformin Extended-Release Tablets (Ⅰ) and (Ⅲ) from the National Medical Products Administration [1] Company Summary - The newly approved medication is intended for adult patients with type 2 diabetes who are suitable for treatment with Saxagliptin and Metformin, aimed at improving blood glucose control [1] - The product is not indicated for patients with type 1 diabetes or diabetic ketoacidosis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which are prescription drugs that assist in the treatment of Parkinson's disease and end-of-dose wearing-off phenomena, classified as a Category B item in the medical insurance directory [1] Group 1 - The approved drug is expected to generate approximately 286 million yuan in sales for public medical institutions in China in 2024 [1] - This approval enhances the company's formulation product portfolio and improves its overall competitiveness [1] - The sales of the drug may be influenced by policies and market factors, leading to uncertainties [1]

新华制药公告称，其全资子公司新达制药收到国家药监局核准签发的沙格列汀二甲双胍缓释片（Ⅰ）、 （Ⅲ）《药品注册证书》。本品配合饮食和运动治疗，适用于2型糖尿病成人患者，为医保目录乙类品 种。2024年中国公立医疗机构该药品销售额约4.19亿元。获批有利于丰富公司降糖制剂系列、提升综合 竞争力，但药品销售受多种因素影响，存在不确定性。 ...